Tag: GlobeNewswire

Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo^® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation

Final Phase 2 analysis explores potential of Libtayo before surgery (neoadjuvant treatment) for patients with resectable CSCC

New data explore inhibition of Factor XI for cancer-associated thrombosis, a leading cause of cancer death, where bleeding risk limits use of anticoagulants

TARRYTOWN, N.Y., Oct. 06, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of new clinical research at the European Society for Medical Oncology (ESMO) Congress 2026, taking place from October 23-27 in Madrid, Spain. Highlights from the company’s 10 abstracts will cover new data and analyses from trials in cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC), ovarian cancer, melanoma and cancer-associated thrombosis.

“At ESMO, we look forward to sharing data across a range of conditions reflecting the breadth of our research,” said Israel Lowy, M.D., Ph.D., Clinical Development Unit Head, Oncology, at Regeneron. “For the first time, we’re showcasing how our work extends beyond the treatment of cancer itself, and addresses some of the complex challenges patients face as a result of their disease. Together, these data reflect our broader commitment to advancing comprehensive cancer care for patients.”

Highlights include:

• Adjuvant treatment with Libtayo in adults with CSCC with high risk of recurrence after surgery and radiation: Late-breaking overall survival (OS) data at approximately 3.5 years follow-up from the C-POST Phase 3 trial will provide further evidence supporting Libtayo as the standard of care in this indication. 
• Neoadjuvant treatment with Libtayo in stage II-IV CSCC: Data include the final analysis of Phase 2 results, which represent the most mature data set in patients treated with Libtayo prior to surgery.
• Factor XI antibodies (cenvacibart and amrecibart) as a potential approach to reducing thrombosis in patients with cancer: Data include a Phase 2 sub-analysis and modeling in catheter-related VTE, plus an update on the Phase 3 ROXI-CAT-II trial.

The full list of Regeneron presentations at ESMO are as follows:  

Abstract Title	Abstract	Presenter	Session Date/Time (CET)
Skin Cancer
C-POST Phase 3 trial of adjuvant cemiplimab vs. placebo for high-risk CSCC: OS update at approximately 3.5 years’ median follow-up	LBA: 59	Danny Rischin	Sunday October 25, 10:15-11:45
A Phase 2 study of neoadjuvant cemiplimab for Stage II–IV CSCC: final analysis	Poster presentation: 2490P	Neil D. Gross	Saturday October 24, 12:00-12:45
Long-term Overall Survival (OS) with Fianlimab (FIAN) plus Cemiplimab (Cemi) in Advanced Melanoma (aMel): Survival Follow-up of a Phase 1 Study	Poster presentation: 2091P	Omid Hamid	Saturday October 24, 12:00-12:45
Lung Cancer
Impact of objective response on PROs in patients receiving cemiplimab + chemotherapy vs. placebo + chemotherapy for aNSCLC: EMPOWER-Lung 3 Part 2	Poster presentation: 2714P	Konstantin Penkov	Monday October 26, 12:00-12:45
CEMI-LUNG, a European-based observational study to assess cemiplimab real world effectiveness and safety in patients with advanced non-small cell lung cancer	Poster presentation: 2580P	Jesus Corral Jaime	Monday October 26, 12:00-12:45
Ovarian Cancer
Circulating tumor DNA (ctDNA), cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) associate with survival outcomes in patients with platinum-resistant ovarian cancer treated with ubamatamab	Poster presentation: 1957P	Jung-Yun Lee	Saturday October 24, 12:00-12:45
A Phase 1/2 study of REGN5668 (ubamatamab) (mucin 16 [MUC16] × cluster of differentiation [CD]28 costimulatory bispecific antibody), in combination with other targeted therapies, in patients with recurrent ovarian cancer or endometrial cancer: Trial in progress update	ePoster presentation: 1445eTiP	Roisin E. O’Cearbhaill	N/A
Thrombosis (cenvacibart [REGN7508] and amrecibart [REGN9933])
Phase 3 trial-in-progress evaluating cenvacibart for the treatment and secondary prevention of venous thromboembolism (VTE) in participants with solid and hematologic cancers (ROXI-CAT-II)	ePoster presentation: 1534eTiP	Andrés J. Muñoz	N/A
Sub-analysis of a Phase 2 study investigating amrecibart and cenvacibart for the prevention of contact-mediated VTE in participants with active cancer undergoing peripherally inserted central catheter (PICC) placement (ROXI-CATH)	Poster presentation: 1468P	Jeffrey I. Zwicker	Monday October 26, 12:00-12:45
Population pharmacokinetic/pharmacodynamic modeling of REGN7508Cat in patients with a PICC from ROXI-CATH who have active cancer supports maximal Factor XI pathway inhibition	Poster presentation: 3968P	Jeffrey I. Zwicker	Saturday October 24, 12:00-12:45

The potential uses of neoadjuvant Libtayo in CSCC, ubamatamab, cenvacibart and amrecibart described above are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.

About Regeneron in Cancer 
We aspire to turn revolutionary discoveries into medicines that can transform the lives of those impacted by cancer. Our team around the world is driven to solve the needs and challenges of those affected by one of the most serious diseases of our time.  

Backed by our legacy of scientific innovation and a deep understanding of biology, genetics and the immune system, we’re pursuing potential therapies across more than 30 types of solid tumors and blood cancers. Our cancer strategy is powered by cutting-edge technologies and therapies that can be flexibly combined to investigate potentially transformative treatments for patients. Oncology assets in clinical development comprise nearly half of Regeneron’s pipeline, and include checkpoint inhibitors, bispecific antibodies and costimulatory bispecific antibodies. Our approved PD-1 inhibitor Libtayo serves as the backbone of many of our investigational combinations.  

To complement our extensive in-house capabilities, we collaborate with patients, healthcare providers, governments, biopharma companies and each other to further our shared goals. Together, we are united in the mission to serve as a beacon of transformation in cancer care. 

About Libtayo  
Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron’s proprietary VelocImmune^® technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), CSCC that is advanced or at high risk of recurrence, advanced NSCLC and advanced cervical cancer.

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. FDA. Outside of the U.S., the generic name of Libtayo in its approved indications is cemiplimab. 

The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either conventional or novel therapeutic approaches for other solid tumors. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.   

U.S. FDA-approved Indications
Libtayo is a prescription medicine used to treat:

• Adults with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC):
  • that has spread or cannot be cured by surgery or radiation, or
  • to help prevent CSCC from coming back if your CSCC is at high risk of coming back after it has been removed by surgery and radiation.
• Adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI.
• Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).
  • LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene.
  • LIBTAYO may be used alone as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high “PD-L1,” and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene.

It is not known if Libtayo is safe and effective in children. 

IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS 

What is the most important information I should know about LIBTAYO?
LIBTAYO is a medicine that may treat certain cancers by working with your immune system. LIBTAYO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

• Lung problems: cough, shortness of breath, or chest pain
• Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or have blood or mucus, or severe stomach-area (abdomen) pain or tenderness
• Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach-area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than normal
• Hormone gland problems: headache that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, or changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
• Kidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, or loss of appetite
• Skin problems: rash, itching, skin blistering or peeling, painful sores or ulcers in mouth or nose, throat, or genital area, fever or flu-like symptoms, or swollen lymph nodes
• Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with LIBTAYO. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath or swelling of ankles, confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs, double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight, persistent or severe muscle pain or weakness, muscle cramps, low red blood cells, or bruising
• Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: nausea, vomiting, chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain, or facial swelling
• Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ or tissue transplant that you have had
• Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with LIBTAYO. Your healthcare provider will monitor you for these complications

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with LIBTAYO. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects.

Before you receive LIBTAYO, tell your healthcare provider about all your medical conditions, including if you:

• have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
• have received an organ or tissue transplant, including corneal transplant
• have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
• have received radiation treatment to your chest area
• have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
• are pregnant or plan to become pregnant. LIBTAYO can harm your unborn baby
  Females who are able to become pregnant:
  • Your healthcare provider will give you a pregnancy test before you start treatment
  • You should use an effective method of birth control during your treatment and for at least 4 months after your last dose of LIBTAYO. Talk to your healthcare provider about birth control methods that you can use during this time
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LIBTAYO

• are breastfeeding or plan to breastfeed. It is not known if LIBTAYO passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of   LIBTAYO

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of LIBTAYO when used alone to treat CSCC that has spread or cannot be cured by surgery or radiation, BCC, or NSCLC include tiredness, muscle or bone pain, rash, diarrhea, and low levels of red blood cells (anemia).

The most common side effects of LIBTAYO when used alone to help prevent CSCC from coming back include rash and itching.

The most common side effects of LIBTAYO when used in combination with platinum-containing chemotherapy to treat NSCLC include hair loss, muscle or bone pain, nausea, tiredness, numbness, pain, tingling, or burning in your hands or feet, and decreased appetite.

These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals at 1-877-542-8296.

Please see full Prescribing Information, including Medication Guide.

About Regeneron’s VelocImmune^® Technology
Regeneron’s VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron’s co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite^® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent^® (dupilumab), Libtayo^® (cemiplimab-rwlc), Praluent^® (alirocumab), Kevzara^®, Evkeeza^® (evinacumab-dgnb), Inmazeb^® (atoltivimab, maftivimab and odesivimab-ebgn), Veopoz^® (pozelimab-bbfg) and Pasatru™ (garetosmab-grts). In addition, REGEN-COV^® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. A total of 11 antibody and bispecific products have been approved or authorized worldwide that were invented or derived using VelocImmune technologies.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite^®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center^® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Libtayo^® (cemiplimab) as an adjuvant or neoadjuvant treatment for high-risk cutaneous squamous cell carcinoma, Regeneron’s Factor XI antibodies (cenvacibart and amrecibart) as a potential approach to reducing thrombosis in patients with cancer, and the other clinical programs discussed or referenced in this press release; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as those referenced above; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above); the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA^® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Contacts:

Media Relations  Taylor Ramsey Skott Tel: +1 914-409-2381 taylor.ramsey@regeneron.com

Investor Relations Mark Hudson Tel: +1 914-847-3482 mark.hudson@regeneron.com

“This update confirms the Lundberg Deposit as a large, pit-constrained copper-zinc resource in one of Newfoundland’s most prolific mining districts and a cornerstone for development of the Buchans District, including Canterra’s other hub-and-spoke deposits.” – Chris Pennimpede, President and CEO

Highlights – 2026 Lundberg Mineral Resource Estimate (effective September 2, 2026)

• 55% increase in Indicated tonnage. The Lundberg Deposit now hosts 26.1 million tonnes (Mt) in the Indicated category, compared with 16.8 Mt in the 2019 estimate, reflecting 4,779 m of drilling completed since acquiring the project in 2024 together with an optimized pit shell at updated metal prices.
• 34% increase in Indicated contained copper equivalent (“CuEq”). 226 thousand tonnes (kt) of CuEq, including 95 kt of copper, 342 kt of zinc and 146 kt of lead, together with 4.2 million ounces of silver and 51,000 ounces of gold contained in the Indicated category. Copper is the largest contributor to CuEq value (approximately 42%).
• 97% of Mineral Resource tonnage is in the Indicated category. The resource is constrained within an optimized pit shell with an overall strip ratio of 3.16:1 (waste to mineralized material), providing a well-defined, open-pit resource base.
• High-grade growth at Two Level zone. Inferred resource grade of 1.54% CuEq includes the massive sulphide mineralization of the Two Level zone. Follow-up drilling will target opportunities to expand the resource, increase grade and upgrade resource confidence.
• Near-resource exploration. The 2.5 km Mine Trend extending northwest of the Lundberg resource represents a high-priority, near-resource exploration target, with potential to expand the resource through drilling at the limits of the resource and on extensions of the existing high-grade underground mine workings.
• A brownfields platform for district growth. The expanded resource strengthens the foundation for evaluating development options across the Company’s central Newfoundland portfolio. The high-grade satellite deposits within a 45 km radius of Lundberg offer potential opportunities to grow the district’s resource inventory, and a shared processing or development concept remains a priority.
• Extensive exploration drilling underway with results expected into 2027. Results are pending for 6,000 m of drilling, to be reported through the remainder of the year and into 2027.

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Canterra Minerals Corporation (TSXV: CTM) (OTCQB: CTMCF) (FSE: DXZB) (“Canterra” or the “Company”) is pleased to announce an updated Mineral Resource Estimate (the “2026 MRE”) for the Lundberg Deposit, part of its 100%-owned Buchans Project in central Newfoundland. The 2026 MRE is constrained within an optimized pit shell and provides a strong foundation for the next phase of exploration and technical evaluation at Buchans, including the integration of satellite deposits.

Chris Pennimpede, President and CEO of Canterra, commented:

“Lundberg now hosts 226 kt of contained copper equivalent in the Indicated category, including significant zinc, lead, silver and gold. Having significantly increased the deposit’s metal inventory, we now expect work at Lundberg to shift towards delineating the high-grade Two Level zone, testing extensions of the deposit and systematically drilling the Mine Trend, where significant opportunities remain for Buchans-style discoveries. Together with continued exploration at our other satellite deposits, the expanded Lundberg resource will serve as the foundation for our broader district development strategy.”

Video Overview

Chris Pennimpede, Canterra’s President and CEO, discusses the Lundberg resource update and the Company’s exploration priorities in this video overview. Click here to watch. The full Mineral Resource tables, assumptions and qualifications are provided in this release.

2026 Lundberg Mineral Resource Estimate

The 2026 MRE was prepared by Matthew Harrington, P.Geo., of Mercator Geological Services Limited (“Mercator”) and is summarized in Table 1, which presents tonnes and grades together with contained metal by Mineral Resource category.

Table 1. Lundberg Deposit Mineral Resource Estimate – Effective Date September 2, 2026

	Tonnes	Cu	Zn	Pb	Ag	Au	CuEq
Grade	(Mt)	(%)	(%)	(%)	(g/t)	(g/t)	(%)
Indicated	26.08	0.36	1.31	0.56	5.02	0.06	0.87
Inferred	0.87	0.48	2.21	1.13	20.87	0.28	1.54
Contained metal		(kt)	(kt)	(kt)	(Moz)	(koz)	(kt)
Indicated		94.8	341.6	146.2	4.21	51.4	226.2
Inferred		4.2	19.2	9.9	0.58	7.8	13.4

Contained metal is in situ and does not represent recovered metal. Contained metal and CuEq grades are calculated from unrounded tonnes and grades before rounding for presentation. Mt = million tonnes; kt = thousand tonnes; Moz = million ounces; koz = thousand ounces. A complete statement of Mineral Resources, including the accompanying notes, can be found in Table 4 of this release.

Table 2. Comparison of the 2026 MRE with the 2019 MRE (now historical) by Mineral Resource category

	Indicated				Inferred
	2019 MRE	2026 MRE	Change		2019 MRE	2026 MRE	Change
Tonnes (Mt)	16.79	26.08	+55	%	0.38	0.87	+129	%
Contained metal
Cu (kt)	70.5	94.8	+34	%	1.4	4.2	+200	%
Zn (kt)	256.9	341.6	+33	%	7.7	19.2	+149	%
Pb (kt)	107.5	146.2	+36	%	3.9	9.9	+154	%
Ag (Moz)	3.07	4.21	+37	%	0.27	0.58	+115	%
Au (koz)	37.8	51.4	+36	%	3.8	7.8	+105	%
CuEq (kt)(1)	168.5	226.2	+34	%	5.2	13.4	+158	%
Grade
Cu (%)	0.42	0.36	−14	%	0.36	0.48	+33	%
Zn (%)	1.53	1.31	−14	%	2.03	2.21	+9	%
Pb (%)	0.64	0.56	−13	%	1.01	1.13	+12	%
Ag (g/t)	5.69	5.02	−12	%	22.35	20.87	−7	%
Au (g/t)	0.07	0.06	−14	%	0.31	0.28	−10	%
CuEq (%)(1)	1.00	0.87	−13	%	1.38	1.54	+12	%

Percentage changes are calculated from unrounded quantities and may differ from changes calculated from the rounded figures shown. 2019 contained metal is calculated from the published 2019 tonnes and grades. (1) 2019 CuEq grades and contained CuEq have been recalculated using the 2026 MRE metal prices, recoveries and payability factors (Note 7 to Table 1) to allow a like-for-like comparison and differ from the CuEq values originally published with the 2019 MRE.

Table 3. Principal economic assumptions – 2019 MRE and 2026 MRE

	Unit	2019 MRE	2026 MRE	Change
Copper	US$/lb	3.00	4.97	+66	%
Zinc	US$/lb	1.20	1.35	+13	%
Lead	US$/lb	1.00	0.95	−5	%
Silver	US$/oz	17.00	42.30	+149	%
Gold	US$/oz	1,250.00	3,285.90	+163	%
NSR cut-off	US$/t	20.00	20.40	+2	%

2026 MRE metal prices and NSR cut-off as set out in Notes 3 and 8 to Table 1. Percentage changes are calculated from the prices shown.

Figure 1. Longitudinal view comparing the 2019 (blue) and 2026 (red) Lundberg Mineral Resource extents and constraining pit shells; in the inset plan view, the black outline marks the 2026 shell. The shells are resource reporting constraints, not proposed mine plans.

Resource Growth and the Buchans District Opportunity

Canterra’s 2024–2026 exploration has defined additional stockwork mineralization at greater depth, extended the deposit to the northeast and down plunge to the northwest, and defined additional massive to brecciated sulphide mineralization at Two Level (Figure 2). The Two Level mineralization, a horizon of transported massive sulphide that plunges moderately northward, is continuous with historical Two Level mining and remains open to the north, east and west. It contributes to the Inferred resource and is a priority for potential expansion and upgrading.

Previous drilling demonstrates the grade potential at Two Level:

• Hole H-25-3542 intersected 4.45 m grading 1.11% Cu, 11.38% Zn, 7.02% Pb, 125.5 g/t Ag and 1.24 g/t Au (7.73% CuEq) from 188.90 m to 193.35 m downhole (reported November 19, 2025; estimated true widths approximately 90% of core length), expanding the zone’s mineralized footprint to approximately 200 m by 50 m.
• Hole H-26-3563 intersected 1.65 m grading 0.63% Cu, 6.11% Zn, 3.43% Pb, 92.3 g/t Ag and 0.69 g/t Au (4.34% CuEq) from 165.75 m to 167.40 m downhole (reported June 3, 2026; estimated true widths approximately 80–90% of core length).

Figure 2. Oblique view of the modelled Lundberg and Two Level mineralization domains relative to the 2026 Mineral Resource reporting pit shell. Remnant massive sulphide domains are shown in dark blue; the inset shows their position in plan view.

These results support further testing of Two Level along strike and at depth. Canterra will also use the updated Lundberg model, historical mine records, recent drilling and geophysical results to rank targets along the Buchans Mine Trend. The Two Level zone and areas beyond the Lundberg pit shell provide opportunities to test for additional high-grade massive sulphide mineralization near the past-producing orebodies. Follow-up drilling will focus on targets with the strongest combined geological and geophysical support (Figure 3). In parallel, the Company intends to define the scope of metallurgical testing to advance its assessment of processing options.

Figure 3. Plan view of the Buchans Mine Trend showing the 2026 Lundberg Mineral Resource outline, historical mine areas, Two Level horizon and priority areas for follow-up exploration. Target outlines indicate areas for investigation and do not represent Mineral Resources.

Beyond the current resource, Canterra has identified prospects and targets for additional high-grade Buchans-style deposits, including mineralized trends that remain underexplored at depth and geophysical anomalies identified by deep-seeking surveys completed in 2025 and 2026. The Company intends to use this growing geological and geophysical dataset to prioritize targets with the potential to expand known mineralization or deliver new discoveries, which could broaden the opportunities for future development at Buchans.

The Lemarchant satellite deposit adds another avenue for resource growth and discovery within Canterra’s central Newfoundland portfolio. Exploration at this satellite deposit is targeting extensions to known mineralization and new deposits that could complement the longer-term vision for a hub-and-spoke development strategy centred on the Buchans Project (Figure 4).

Figure 4. Canterra’s projects in central Newfoundland, showing the Buchans District with the Lundberg Deposit, the satellite deposits and the Wilding Gold Project in their regional setting.

Pit Shell and Infrastructure

The Lundberg Deposit is at a brownfields past-producing mine site and is adjacent to the community of Buchans and has access to road, power and water infrastructure. The optimized pit shell was developed to assess reasonable prospects for eventual economic extraction; it does not represent an estimate of Mineral Reserves or a proposed mine plan, and it was not constrained by surface infrastructure. The shell has an overall strip ratio of 3.16:1 (waste to mineralized material). Historical mining within the resource area has been accounted for as described in Note 12 to Table 1, and the topographic surface has been modified to accommodate the Lucky Strike glory hole. Figure 5 shows the distribution of modelled NSR values within the pit shell.

Figure 5. Oblique sectional view looking northeast showing modelled NSR values (US$/t) within the 2026 Lundberg Mineral Resource reporting pit shell. The inset identifies the section line in plan view.

Ongoing Exploration in the District

At the Lemarchant satellite deposit, drilling is underway and forms part of a 6,000 m district exploration program, with results pending and to be reported through the remainder of the year and into 2027. Gravity survey results are expected in Q4 2026. Together, drilling and geophysical interpretation are intended to refine targeting and identify further opportunities for resource growth and discovery (Figure 6).

Figure 6. Lemarchant Project exploration target areas.

Drill Hole Database, QA/QC and Data Verification

The resource database is a subset of Canterra’s Buchans District drill hole database. A total of 414 drill holes occur within the modelled limits of the mineralized zones, of which 299 have sampling results for 10,508 m of assayed intervals. Canterra completed 23 diamond drill holes totalling 4,778.7 m at Lundberg and Two Level from 2024 up to the MRE database cut-off date of August 3, 2026, of which 20 contribute to the 2026 MRE. An additional hole, H-26-3568, was completed at Lundberg after the database cut-off date and will be considered in future resource estimation.

Canterra’s drilling programs use quality assurance and quality control procedures that include reference standards, blanks, duplicates and independent check assays. Samples comprise half of the sawn NQ core, with the remaining half retained. Assays from Canterra’s 2024–2026 programs were prepared and analyzed by SGS Canada (“SGS”) or Eastern Analytical Ltd. (“Eastern”). SGS samples were prepared in Grand Falls-Windsor and analyzed in Burnaby using fusion and ICP-OES methods for base metals, with separate silver and gold methods and over-limit procedures. Eastern samples were prepared at its Springdale laboratory and analyzed by 30 g gold fire assay, with metals by four-acid ICP-OES multi-element analysis and atomic absorption for over-limit results. Representative pulps were also submitted to ALS Geochemistry in Moncton for independent check assays.

The drill hole database supporting the 2019 MRE was carried forward and supplemented with Canterra’s exploration results. Canterra drill holes underwent verification against original assay records, collar information, downhole surveys and geological interval data. Earlier holes comprise pre-2007 drilling and programs attributed to Buchans Minerals Corporation (“BMC”) and related operators during 2007–2024. Compilation and validation of the pre-2007 information included checks against original assay records, historical maps, sections and plans, together with relogging, resampling and twin drilling completed during BMC’s operations.

BMC drilling programs in 2008, 2012, 2014/2015 and 2018 were subject to validation of collar data, downhole surveys, geological intervals, original assay certificates and sample records. Several core sampling programs were analyzed by both Eastern and ALS Geochemistry; where both sets of results were available, Eastern results were given priority.

For partially sampled holes, included unsampled intervals were assigned a grade of zero for all metals. In holes with limited or no sampling, unsampled intervals were either assigned zero grade or excluded. Unsampled holes were excluded where compiled geological data supported the presence of a well-mineralized stockwork zone but analytical results were unavailable. Unsampled or partially sampled intervals in historical holes that were subsequently twinned and sampled during BMC and/or Canterra programs were also excluded, with the more recent information used instead.

Matthew Harrington, P.Geo., the Qualified Person (“QP”) responsible for the 2026 MRE, visited the property in 2018, 2024 and 2026, completing independent witness check sample programs during the 2018 and 2026 visits with satisfactory results. The QP verified the data underlying the 2026 MRE and is of the opinion that it is acceptable for Mineral Resource estimation purposes.

Exploration Targets and Historical Estimates

Exploration targets outside the reported Lundberg Mineral Resource are conceptual and include historical mineral resource estimates. A QP has not done sufficient work to classify the historical estimates as current Mineral Resources or Mineral Reserves, and Canterra is not treating historical estimates related to the satellite deposits as current Mineral Resources or Mineral Reserves. Further exploration is required to determine whether they can support Mineral Resources, there is no certainty that new resources will be defined, and references to satellite deposits do not imply that their resources have been incorporated into the 2026 MRE.

Table 4. Lundberg Deposit Mineral Resource Estimate – Effective Date September 2, 2026

	Tonnes	Cu	Zn	Pb	Ag	Au	CuEq
Grade	(Mt)	(%)	(%)	(%)	(g/t)	(g/t)	(%)
Indicated	26.08	0.36	1.31	0.56	5.02	0.06	0.87
Inferred	0.87	0.48	2.21	1.13	20.87	0.28	1.54
Contained metal		(kt)	(kt)	(kt)	(Moz)	(koz)	(kt)
Indicated		94.8	341.6	146.2	4.21	51.4	226.2
Inferred		4.2	19.2	9.9	0.58	7.8	13.4

Contained metal is in situ and does not represent recovered metal. Contained metal and CuEq grades are calculated from unrounded tonnes and grades before rounding for presentation. Mt = million tonnes; kt = thousand tonnes; Moz = million ounces; koz = thousand ounces.

Notes to Tables 1 and 4

1. Mineral Resources are defined within an optimized pit shell using pit slope angles between 33° and 50°, based on a pit slope stability study by The Mines Group Inc. (2013). The optimized pit shell has an overall strip ratio of 3.16:1 (waste to mineralized material).
2. Pit optimization costs include mineralized material mining costs of US$3.60/t, waste mining costs of US$3.00/t, processing costs of US$18.00/t, general and administrative costs of US$2.40/t, and an exchange rate of C$1.37 per US$1.00.
3. Metal price assumptions are US$4.97/lb Cu, US$1.35/lb Zn, US$0.95/lb Pb, US$42.30/oz Ag and US$3,285.90/oz Au.
4. Metallurgical recoveries to concentrates are based on the “Centralized Milling of Newfoundland Base Metal Deposits – Bench Scale DMS and Flotation Test Program” (Thibault & Associates Inc., 2017). Metal recoveries are 83.0% Cu, 13.3% Au, and 7.84% Ag in the copper concentrate, 84.31% Pb, 10.54% Au, and 50.26% Ag in the lead concentrate, and 87.20% Zn, 8.28% Au, and 14.77% Ag in the zinc concentrate.
5. Net Smelter Return (“NSR”) US$/t values were determined for each resource model block using an NSR calculator. The NSR calculator incorporates the stated metal prices, metallurgical recoveries to concentrates, concentrate payable factors, and current shipping and smelting terms for similar concentrates.
6. The NSR calculator’s payable assumptions for each metal in each concentrate result in overall recovery and payability factors (payable factor × metal recovery) of 80.18% Cu, 80.09% Pb, 74.12% Zn, 65.69% Ag and 23.05% Au.
7. Copper equivalent (CuEq) grades were calculated using the stated metal prices, metallurgical recoveries to concentrates and concentrate payable factors: CuEq (%) = Cu (%) + (Pb (%) × 0.1909) + (Zn (%) × 0.2511) + (Ag (g/t) × 0.0102) + (Au (g/t) × 0.2772).
8. Mineral Resources are reported at a cut-off of US$20.40/t NSR within the optimized pit shell and are considered to reflect reasonable prospects for eventual economic extraction by open pit mining methods.
9. Mineral Resources were interpolated using inverse distance squared methods applied to 1.5 m downhole assay composites constrained within three-dimensional solid models representing stockwork and massive sulphide mineralization. No grade capping was applied.
10. An interpolated inverse distance squared bulk density model (g/cm³) was applied.
11. The block model uses blocks measuring 5 m (x) by 5 m (y) by 5 m (z), with a minimum block size of 0.625 m (x) by 0.625 m (y) by 0.625 m (z).
12. Mineral Resources were depleted for the Buchans Lucky Strike glory hole and historical mining. Historical stopes are assumed to be sand-filled with a density of 1.92 g/cm³, and historical development workings are assumed to be open void space.
13. The classification of the current Mineral Resource Estimate into Indicated and Inferred is consistent with the Canadian Institute of Mining, Metallurgy, and Petroleum (“CIM”) Definition Standards for Mineral Resources and Mineral Reserves, May 10, 2014 (“CIM Definition Standards”).
14. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. There is no certainty that all or any part of the estimated Mineral Resources will be converted into Mineral Reserves. An Inferred Mineral Resource has a lower level of confidence than a Measured or Indicated Mineral Resource. It is reasonably expected that the majority of Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration.
15. Mineral Resource tonnages have been rounded to the nearest 10,000 tonnes. Totals may vary due to rounding.
16. The MRE was completed in consideration of the CIM Estimation of Mineral Resources and Mineral Reserves Best Practice Guidelines (November 29, 2019).
17. The technical report in support of the 2026 MRE will be filed by the Company within 45 days of this news release.

Qualified Persons

Matthew Harrington, P.Geo., of Mercator, is an independent Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) and is responsible for the technical disclosure regarding the 2026 MRE contained in this news release.

Paul Moore, MSc., P.Geo. (NL), Vice President of Exploration, is the Qualified Person for the Company and has reviewed and approved the other scientific and technical information in this news release.

Newfoundland and Labrador Junior Exploration Assistance

Canterra would like to acknowledge financial support it received from the Government of Newfoundland and Labrador’s Junior Exploration Assistance Program related to completion of its 2024 and 2025 programs, and any support it may receive for its 2026 exploration programs in the Buchans District.

About Canterra Minerals

Canterra is a diversified minerals exploration company focused on critical minerals and gold in central Newfoundland. The Company’s projects include seven mineral deposits located in close proximity to the world-renowned, past-producing Buchans Mine and Teck Resources’ Duck Pond Mine, which collectively produced copper, zinc, lead, silver and gold. Several of Canterra’s deposits support current and historical Mineral Resource Estimates prepared in accordance with National Instrument 43-101 and the Canadian Institute of Mining, Metallurgy, and Petroleum Definition Standards for Mineral Resources and Mineral Reserves. Canterra’s gold projects are located on trend of Equinox Gold’s Valentine Mine and cover an approximately 55 km extension of the same structural corridor that hosts gold mineralization within Equinox Gold’s mine. Past drilling by Canterra and others within the Company’s gold projects intersected multiple occurrences of orogenic-style gold mineralization within a large land position that remains underexplored.

ON BEHALF OF THE BOARD OF CANTERRA MINERALS CORPORATION

Chris Pennimpede
President & CEO

Additional information about the Company is available at www.canterraminerals.com
For further information, please contact: +1 (604) 687-6644
Email: info@canterraminerals.com

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking information within the meaning of applicable Canadian securities legislation, including statements concerning the estimated mineral resources, exploration potential, planned drilling and metallurgical work, potential district development strategies, further technical evaluation, the timing of the supporting technical report and anticipated exploration assistance funding. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statements that discuss predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” occur or be achieved) are not statements of historical fact and may be forward-looking statements. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include risks associated with possible accidents and other risks associated with mineral exploration operations, the risk that assay, geophysical or metallurgical results will not support the Company’s interpretations or continued exploration, the risk that further technical work results in revisions to the mineral resource estimate, volatility in copper, zinc, lead, silver and gold prices, the risk that the Company will encounter unanticipated geological factors, the possibility that the Company may not be able to secure permitting and other governmental clearances necessary to carry out the Company’s exploration plans, the risk that the Company will not be able to raise sufficient funds to carry out its business plans, and the risk of political uncertainties and regulatory or legal changes that might interfere with the Company’s business and prospects, as well as those risks and uncertainties identified and reported in the Company’s public filings under its SEDAR+ profile at www.sedarplus.ca. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/461e170e-9068-416a-8ad6-c03e25da757a

https://www.globenewswire.com/NewsRoom/AttachmentNg/6e5ed0fe-4b18-4899-a706-7e45198fb299

https://www.globenewswire.com/NewsRoom/AttachmentNg/9b0a31db-ae0e-46f9-9910-3bdd1e7b8d1b

https://www.globenewswire.com/NewsRoom/AttachmentNg/8aea26a8-682f-4c80-b1cf-42ee9b892ba1

https://www.globenewswire.com/NewsRoom/AttachmentNg/674663d1-7b4a-4165-91b8-eb681fd6e968

https://www.globenewswire.com/NewsRoom/AttachmentNg/c8cc9810-9c56-4ee7-a01b-38090c8bd074

“This update confirms the Lundberg Deposit as a large, pit-constrained copper-zinc resource in one of Newfoundland’s most prolific mining districts and a cornerstone for development of the Buchans District, including Canterra’s other hub-and-spoke deposits.” – Chris Pennimpede, President and CEO

Highlights – 2026 Lundberg Mineral Resource Estimate (effective September 2, 2026)

• 55% increase in Indicated tonnage. The Lundberg Deposit now hosts 26.1 million tonnes (Mt) in the Indicated category, compared with 16.8 Mt in the 2019 estimate, reflecting 4,779 m of drilling completed since acquiring the project in 2024 together with an optimized pit shell at updated metal prices.
• 34% increase in Indicated contained copper equivalent (“CuEq”). 226 thousand tonnes (kt) of CuEq, including 95 kt of copper, 342 kt of zinc and 146 kt of lead, together with 4.2 million ounces of silver and 51,000 ounces of gold contained in the Indicated category. Copper is the largest contributor to CuEq value (approximately 42%).
• 97% of Mineral Resource tonnage is in the Indicated category. The resource is constrained within an optimized pit shell with an overall strip ratio of 3.16:1 (waste to mineralized material), providing a well-defined, open-pit resource base.
• High-grade growth at Two Level zone. Inferred resource grade of 1.54% CuEq includes the massive sulphide mineralization of the Two Level zone. Follow-up drilling will target opportunities to expand the resource, increase grade and upgrade resource confidence.
• Near-resource exploration. The 2.5 km Mine Trend extending northwest of the Lundberg resource represents a high-priority, near-resource exploration target, with potential to expand the resource through drilling at the limits of the resource and on extensions of the existing high-grade underground mine workings.
• A brownfields platform for district growth. The expanded resource strengthens the foundation for evaluating development options across the Company’s central Newfoundland portfolio. The high-grade satellite deposits within a 45 km radius of Lundberg offer potential opportunities to grow the district’s resource inventory, and a shared processing or development concept remains a priority.
• Extensive exploration drilling underway with results expected into 2027. Results are pending for 6,000 m of drilling, to be reported through the remainder of the year and into 2027.

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Canterra Minerals Corporation (TSXV: CTM) (OTCQB: CTMCF) (FSE: DXZB) (“Canterra” or the “Company”) is pleased to announce an updated Mineral Resource Estimate (the “2026 MRE”) for the Lundberg Deposit, part of its 100%-owned Buchans Project in central Newfoundland. The 2026 MRE is constrained within an optimized pit shell and provides a strong foundation for the next phase of exploration and technical evaluation at Buchans, including the integration of satellite deposits.

Chris Pennimpede, President and CEO of Canterra, commented:

“Lundberg now hosts 226 kt of contained copper equivalent in the Indicated category, including significant zinc, lead, silver and gold. Having significantly increased the deposit’s metal inventory, we now expect work at Lundberg to shift towards delineating the high-grade Two Level zone, testing extensions of the deposit and systematically drilling the Mine Trend, where significant opportunities remain for Buchans-style discoveries. Together with continued exploration at our other satellite deposits, the expanded Lundberg resource will serve as the foundation for our broader district development strategy.”

Video Overview

Chris Pennimpede, Canterra’s President and CEO, discusses the Lundberg resource update and the Company’s exploration priorities in this video overview. Click here to watch. The full Mineral Resource tables, assumptions and qualifications are provided in this release.

2026 Lundberg Mineral Resource Estimate

The 2026 MRE was prepared by Matthew Harrington, P.Geo., of Mercator Geological Services Limited (“Mercator”) and is summarized in Table 1, which presents tonnes and grades together with contained metal by Mineral Resource category.

Table 1. Lundberg Deposit Mineral Resource Estimate – Effective Date September 2, 2026

	Tonnes	Cu	Zn	Pb	Ag	Au	CuEq
Grade	(Mt)	(%)	(%)	(%)	(g/t)	(g/t)	(%)
Indicated	26.08	0.36	1.31	0.56	5.02	0.06	0.87
Inferred	0.87	0.48	2.21	1.13	20.87	0.28	1.54
Contained metal		(kt)	(kt)	(kt)	(Moz)	(koz)	(kt)
Indicated		94.8	341.6	146.2	4.21	51.4	226.2
Inferred		4.2	19.2	9.9	0.58	7.8	13.4

Contained metal is in situ and does not represent recovered metal. Contained metal and CuEq grades are calculated from unrounded tonnes and grades before rounding for presentation. Mt = million tonnes; kt = thousand tonnes; Moz = million ounces; koz = thousand ounces. A complete statement of Mineral Resources, including the accompanying notes, can be found in Table 4 of this release.

Table 2. Comparison of the 2026 MRE with the 2019 MRE (now historical) by Mineral Resource category

	Indicated				Inferred
	2019 MRE	2026 MRE	Change		2019 MRE	2026 MRE	Change
Tonnes (Mt)	16.79	26.08	+55	%	0.38	0.87	+129	%
Contained metal
Cu (kt)	70.5	94.8	+34	%	1.4	4.2	+200	%
Zn (kt)	256.9	341.6	+33	%	7.7	19.2	+149	%
Pb (kt)	107.5	146.2	+36	%	3.9	9.9	+154	%
Ag (Moz)	3.07	4.21	+37	%	0.27	0.58	+115	%
Au (koz)	37.8	51.4	+36	%	3.8	7.8	+105	%
CuEq (kt)(1)	168.5	226.2	+34	%	5.2	13.4	+158	%
Grade
Cu (%)	0.42	0.36	−14	%	0.36	0.48	+33	%
Zn (%)	1.53	1.31	−14	%	2.03	2.21	+9	%
Pb (%)	0.64	0.56	−13	%	1.01	1.13	+12	%
Ag (g/t)	5.69	5.02	−12	%	22.35	20.87	−7	%
Au (g/t)	0.07	0.06	−14	%	0.31	0.28	−10	%
CuEq (%)(1)	1.00	0.87	−13	%	1.38	1.54	+12	%

Percentage changes are calculated from unrounded quantities and may differ from changes calculated from the rounded figures shown. 2019 contained metal is calculated from the published 2019 tonnes and grades. (1) 2019 CuEq grades and contained CuEq have been recalculated using the 2026 MRE metal prices, recoveries and payability factors (Note 7 to Table 1) to allow a like-for-like comparison and differ from the CuEq values originally published with the 2019 MRE.

Table 3. Principal economic assumptions – 2019 MRE and 2026 MRE

	Unit	2019 MRE	2026 MRE	Change
Copper	US$/lb	3.00	4.97	+66	%
Zinc	US$/lb	1.20	1.35	+13	%
Lead	US$/lb	1.00	0.95	−5	%
Silver	US$/oz	17.00	42.30	+149	%
Gold	US$/oz	1,250.00	3,285.90	+163	%
NSR cut-off	US$/t	20.00	20.40	+2	%

2026 MRE metal prices and NSR cut-off as set out in Notes 3 and 8 to Table 1. Percentage changes are calculated from the prices shown.

Figure 1. Longitudinal view comparing the 2019 (blue) and 2026 (red) Lundberg Mineral Resource extents and constraining pit shells; in the inset plan view, the black outline marks the 2026 shell. The shells are resource reporting constraints, not proposed mine plans.

Resource Growth and the Buchans District Opportunity

Canterra’s 2024–2026 exploration has defined additional stockwork mineralization at greater depth, extended the deposit to the northeast and down plunge to the northwest, and defined additional massive to brecciated sulphide mineralization at Two Level (Figure 2). The Two Level mineralization, a horizon of transported massive sulphide that plunges moderately northward, is continuous with historical Two Level mining and remains open to the north, east and west. It contributes to the Inferred resource and is a priority for potential expansion and upgrading.

Previous drilling demonstrates the grade potential at Two Level:

• Hole H-25-3542 intersected 4.45 m grading 1.11% Cu, 11.38% Zn, 7.02% Pb, 125.5 g/t Ag and 1.24 g/t Au (7.73% CuEq) from 188.90 m to 193.35 m downhole (reported November 19, 2025; estimated true widths approximately 90% of core length), expanding the zone’s mineralized footprint to approximately 200 m by 50 m.
• Hole H-26-3563 intersected 1.65 m grading 0.63% Cu, 6.11% Zn, 3.43% Pb, 92.3 g/t Ag and 0.69 g/t Au (4.34% CuEq) from 165.75 m to 167.40 m downhole (reported June 3, 2026; estimated true widths approximately 80–90% of core length).

Figure 2. Oblique view of the modelled Lundberg and Two Level mineralization domains relative to the 2026 Mineral Resource reporting pit shell. Remnant massive sulphide domains are shown in dark blue; the inset shows their position in plan view.

These results support further testing of Two Level along strike and at depth. Canterra will also use the updated Lundberg model, historical mine records, recent drilling and geophysical results to rank targets along the Buchans Mine Trend. The Two Level zone and areas beyond the Lundberg pit shell provide opportunities to test for additional high-grade massive sulphide mineralization near the past-producing orebodies. Follow-up drilling will focus on targets with the strongest combined geological and geophysical support (Figure 3). In parallel, the Company intends to define the scope of metallurgical testing to advance its assessment of processing options.

Figure 3. Plan view of the Buchans Mine Trend showing the 2026 Lundberg Mineral Resource outline, historical mine areas, Two Level horizon and priority areas for follow-up exploration. Target outlines indicate areas for investigation and do not represent Mineral Resources.

Beyond the current resource, Canterra has identified prospects and targets for additional high-grade Buchans-style deposits, including mineralized trends that remain underexplored at depth and geophysical anomalies identified by deep-seeking surveys completed in 2025 and 2026. The Company intends to use this growing geological and geophysical dataset to prioritize targets with the potential to expand known mineralization or deliver new discoveries, which could broaden the opportunities for future development at Buchans.

The Lemarchant satellite deposit adds another avenue for resource growth and discovery within Canterra’s central Newfoundland portfolio. Exploration at this satellite deposit is targeting extensions to known mineralization and new deposits that could complement the longer-term vision for a hub-and-spoke development strategy centred on the Buchans Project (Figure 4).

Figure 4. Canterra’s projects in central Newfoundland, showing the Buchans District with the Lundberg Deposit, the satellite deposits and the Wilding Gold Project in their regional setting.

Pit Shell and Infrastructure

The Lundberg Deposit is at a brownfields past-producing mine site and is adjacent to the community of Buchans and has access to road, power and water infrastructure. The optimized pit shell was developed to assess reasonable prospects for eventual economic extraction; it does not represent an estimate of Mineral Reserves or a proposed mine plan, and it was not constrained by surface infrastructure. The shell has an overall strip ratio of 3.16:1 (waste to mineralized material). Historical mining within the resource area has been accounted for as described in Note 12 to Table 1, and the topographic surface has been modified to accommodate the Lucky Strike glory hole. Figure 5 shows the distribution of modelled NSR values within the pit shell.

Figure 5. Oblique sectional view looking northeast showing modelled NSR values (US$/t) within the 2026 Lundberg Mineral Resource reporting pit shell. The inset identifies the section line in plan view.

Ongoing Exploration in the District

At the Lemarchant satellite deposit, drilling is underway and forms part of a 6,000 m district exploration program, with results pending and to be reported through the remainder of the year and into 2027. Gravity survey results are expected in Q4 2026. Together, drilling and geophysical interpretation are intended to refine targeting and identify further opportunities for resource growth and discovery (Figure 6).

Figure 6. Lemarchant Project exploration target areas.

Drill Hole Database, QA/QC and Data Verification

The resource database is a subset of Canterra’s Buchans District drill hole database. A total of 414 drill holes occur within the modelled limits of the mineralized zones, of which 299 have sampling results for 10,508 m of assayed intervals. Canterra completed 23 diamond drill holes totalling 4,778.7 m at Lundberg and Two Level from 2024 up to the MRE database cut-off date of August 3, 2026, of which 20 contribute to the 2026 MRE. An additional hole, H-26-3568, was completed at Lundberg after the database cut-off date and will be considered in future resource estimation.

Canterra’s drilling programs use quality assurance and quality control procedures that include reference standards, blanks, duplicates and independent check assays. Samples comprise half of the sawn NQ core, with the remaining half retained. Assays from Canterra’s 2024–2026 programs were prepared and analyzed by SGS Canada (“SGS”) or Eastern Analytical Ltd. (“Eastern”). SGS samples were prepared in Grand Falls-Windsor and analyzed in Burnaby using fusion and ICP-OES methods for base metals, with separate silver and gold methods and over-limit procedures. Eastern samples were prepared at its Springdale laboratory and analyzed by 30 g gold fire assay, with metals by four-acid ICP-OES multi-element analysis and atomic absorption for over-limit results. Representative pulps were also submitted to ALS Geochemistry in Moncton for independent check assays.

The drill hole database supporting the 2019 MRE was carried forward and supplemented with Canterra’s exploration results. Canterra drill holes underwent verification against original assay records, collar information, downhole surveys and geological interval data. Earlier holes comprise pre-2007 drilling and programs attributed to Buchans Minerals Corporation (“BMC”) and related operators during 2007–2024. Compilation and validation of the pre-2007 information included checks against original assay records, historical maps, sections and plans, together with relogging, resampling and twin drilling completed during BMC’s operations.

BMC drilling programs in 2008, 2012, 2014/2015 and 2018 were subject to validation of collar data, downhole surveys, geological intervals, original assay certificates and sample records. Several core sampling programs were analyzed by both Eastern and ALS Geochemistry; where both sets of results were available, Eastern results were given priority.

For partially sampled holes, included unsampled intervals were assigned a grade of zero for all metals. In holes with limited or no sampling, unsampled intervals were either assigned zero grade or excluded. Unsampled holes were excluded where compiled geological data supported the presence of a well-mineralized stockwork zone but analytical results were unavailable. Unsampled or partially sampled intervals in historical holes that were subsequently twinned and sampled during BMC and/or Canterra programs were also excluded, with the more recent information used instead.

Matthew Harrington, P.Geo., the Qualified Person (“QP”) responsible for the 2026 MRE, visited the property in 2018, 2024 and 2026, completing independent witness check sample programs during the 2018 and 2026 visits with satisfactory results. The QP verified the data underlying the 2026 MRE and is of the opinion that it is acceptable for Mineral Resource estimation purposes.

Exploration Targets and Historical Estimates

Exploration targets outside the reported Lundberg Mineral Resource are conceptual and include historical mineral resource estimates. A QP has not done sufficient work to classify the historical estimates as current Mineral Resources or Mineral Reserves, and Canterra is not treating historical estimates related to the satellite deposits as current Mineral Resources or Mineral Reserves. Further exploration is required to determine whether they can support Mineral Resources, there is no certainty that new resources will be defined, and references to satellite deposits do not imply that their resources have been incorporated into the 2026 MRE.

Table 4. Lundberg Deposit Mineral Resource Estimate – Effective Date September 2, 2026

	Tonnes	Cu	Zn	Pb	Ag	Au	CuEq
Grade	(Mt)	(%)	(%)	(%)	(g/t)	(g/t)	(%)
Indicated	26.08	0.36	1.31	0.56	5.02	0.06	0.87
Inferred	0.87	0.48	2.21	1.13	20.87	0.28	1.54
Contained metal		(kt)	(kt)	(kt)	(Moz)	(koz)	(kt)
Indicated		94.8	341.6	146.2	4.21	51.4	226.2
Inferred		4.2	19.2	9.9	0.58	7.8	13.4

Contained metal is in situ and does not represent recovered metal. Contained metal and CuEq grades are calculated from unrounded tonnes and grades before rounding for presentation. Mt = million tonnes; kt = thousand tonnes; Moz = million ounces; koz = thousand ounces.

Notes to Tables 1 and 4

1. Mineral Resources are defined within an optimized pit shell using pit slope angles between 33° and 50°, based on a pit slope stability study by The Mines Group Inc. (2013). The optimized pit shell has an overall strip ratio of 3.16:1 (waste to mineralized material).
2. Pit optimization costs include mineralized material mining costs of US$3.60/t, waste mining costs of US$3.00/t, processing costs of US$18.00/t, general and administrative costs of US$2.40/t, and an exchange rate of C$1.37 per US$1.00.
3. Metal price assumptions are US$4.97/lb Cu, US$1.35/lb Zn, US$0.95/lb Pb, US$42.30/oz Ag and US$3,285.90/oz Au.
4. Metallurgical recoveries to concentrates are based on the “Centralized Milling of Newfoundland Base Metal Deposits – Bench Scale DMS and Flotation Test Program” (Thibault & Associates Inc., 2017). Metal recoveries are 83.0% Cu, 13.3% Au, and 7.84% Ag in the copper concentrate, 84.31% Pb, 10.54% Au, and 50.26% Ag in the lead concentrate, and 87.20% Zn, 8.28% Au, and 14.77% Ag in the zinc concentrate.
5. Net Smelter Return (“NSR”) US$/t values were determined for each resource model block using an NSR calculator. The NSR calculator incorporates the stated metal prices, metallurgical recoveries to concentrates, concentrate payable factors, and current shipping and smelting terms for similar concentrates.
6. The NSR calculator’s payable assumptions for each metal in each concentrate result in overall recovery and payability factors (payable factor × metal recovery) of 80.18% Cu, 80.09% Pb, 74.12% Zn, 65.69% Ag and 23.05% Au.
7. Copper equivalent (CuEq) grades were calculated using the stated metal prices, metallurgical recoveries to concentrates and concentrate payable factors: CuEq (%) = Cu (%) + (Pb (%) × 0.1909) + (Zn (%) × 0.2511) + (Ag (g/t) × 0.0102) + (Au (g/t) × 0.2772).
8. Mineral Resources are reported at a cut-off of US$20.40/t NSR within the optimized pit shell and are considered to reflect reasonable prospects for eventual economic extraction by open pit mining methods.
9. Mineral Resources were interpolated using inverse distance squared methods applied to 1.5 m downhole assay composites constrained within three-dimensional solid models representing stockwork and massive sulphide mineralization. No grade capping was applied.
10. An interpolated inverse distance squared bulk density model (g/cm³) was applied.
11. The block model uses blocks measuring 5 m (x) by 5 m (y) by 5 m (z), with a minimum block size of 0.625 m (x) by 0.625 m (y) by 0.625 m (z).
12. Mineral Resources were depleted for the Buchans Lucky Strike glory hole and historical mining. Historical stopes are assumed to be sand-filled with a density of 1.92 g/cm³, and historical development workings are assumed to be open void space.
13. The classification of the current Mineral Resource Estimate into Indicated and Inferred is consistent with the Canadian Institute of Mining, Metallurgy, and Petroleum (“CIM”) Definition Standards for Mineral Resources and Mineral Reserves, May 10, 2014 (“CIM Definition Standards”).
14. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. There is no certainty that all or any part of the estimated Mineral Resources will be converted into Mineral Reserves. An Inferred Mineral Resource has a lower level of confidence than a Measured or Indicated Mineral Resource. It is reasonably expected that the majority of Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration.
15. Mineral Resource tonnages have been rounded to the nearest 10,000 tonnes. Totals may vary due to rounding.
16. The MRE was completed in consideration of the CIM Estimation of Mineral Resources and Mineral Reserves Best Practice Guidelines (November 29, 2019).
17. The technical report in support of the 2026 MRE will be filed by the Company within 45 days of this news release.

Qualified Persons

Matthew Harrington, P.Geo., of Mercator, is an independent Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) and is responsible for the technical disclosure regarding the 2026 MRE contained in this news release.

Paul Moore, MSc., P.Geo. (NL), Vice President of Exploration, is the Qualified Person for the Company and has reviewed and approved the other scientific and technical information in this news release.

Newfoundland and Labrador Junior Exploration Assistance

Canterra would like to acknowledge financial support it received from the Government of Newfoundland and Labrador’s Junior Exploration Assistance Program related to completion of its 2024 and 2025 programs, and any support it may receive for its 2026 exploration programs in the Buchans District.

About Canterra Minerals

Canterra is a diversified minerals exploration company focused on critical minerals and gold in central Newfoundland. The Company’s projects include seven mineral deposits located in close proximity to the world-renowned, past-producing Buchans Mine and Teck Resources’ Duck Pond Mine, which collectively produced copper, zinc, lead, silver and gold. Several of Canterra’s deposits support current and historical Mineral Resource Estimates prepared in accordance with National Instrument 43-101 and the Canadian Institute of Mining, Metallurgy, and Petroleum Definition Standards for Mineral Resources and Mineral Reserves. Canterra’s gold projects are located on trend of Equinox Gold’s Valentine Mine and cover an approximately 55 km extension of the same structural corridor that hosts gold mineralization within Equinox Gold’s mine. Past drilling by Canterra and others within the Company’s gold projects intersected multiple occurrences of orogenic-style gold mineralization within a large land position that remains underexplored.

ON BEHALF OF THE BOARD OF CANTERRA MINERALS CORPORATION

Chris Pennimpede
President & CEO

Additional information about the Company is available at www.canterraminerals.com
For further information, please contact: +1 (604) 687-6644
Email: info@canterraminerals.com

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking information within the meaning of applicable Canadian securities legislation, including statements concerning the estimated mineral resources, exploration potential, planned drilling and metallurgical work, potential district development strategies, further technical evaluation, the timing of the supporting technical report and anticipated exploration assistance funding. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statements that discuss predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” occur or be achieved) are not statements of historical fact and may be forward-looking statements. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include risks associated with possible accidents and other risks associated with mineral exploration operations, the risk that assay, geophysical or metallurgical results will not support the Company’s interpretations or continued exploration, the risk that further technical work results in revisions to the mineral resource estimate, volatility in copper, zinc, lead, silver and gold prices, the risk that the Company will encounter unanticipated geological factors, the possibility that the Company may not be able to secure permitting and other governmental clearances necessary to carry out the Company’s exploration plans, the risk that the Company will not be able to raise sufficient funds to carry out its business plans, and the risk of political uncertainties and regulatory or legal changes that might interfere with the Company’s business and prospects, as well as those risks and uncertainties identified and reported in the Company’s public filings under its SEDAR+ profile at www.sedarplus.ca. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/461e170e-9068-416a-8ad6-c03e25da757a

https://www.globenewswire.com/NewsRoom/AttachmentNg/6e5ed0fe-4b18-4899-a706-7e45198fb299

https://www.globenewswire.com/NewsRoom/AttachmentNg/9b0a31db-ae0e-46f9-9910-3bdd1e7b8d1b

https://www.globenewswire.com/NewsRoom/AttachmentNg/8aea26a8-682f-4c80-b1cf-42ee9b892ba1

https://www.globenewswire.com/NewsRoom/AttachmentNg/674663d1-7b4a-4165-91b8-eb681fd6e968

https://www.globenewswire.com/NewsRoom/AttachmentNg/c8cc9810-9c56-4ee7-a01b-38090c8bd074

Internet, Everywhere, Oct. 06, 2026 (GLOBE NEWSWIRE) — Shopify Inc. (NASDAQ, TSX: SHOP) plans to announce financial results for the quarter ended September 30, 2026 before markets open on Tuesday, November 3, 2026.

Shopify’s management team will host a conference call to discuss third-quarter results at 8:30 a.m. ET on Tuesday, November 3, 2026. The conference call will be available via webcast on the Investor Relations section of Shopify’s website at https://www.shopify.com/investors/events.

An archived replay of the webcast will be available following the conclusion of the call.

About Shopify

Shopify provides essential internet infrastructure for commerce. Shopify’s all-in-one platform makes it easier to start, run, and grow a business, powering sales online, in store, and everywhere in between. Millions of businesses in 175+ countries use Shopify—from entrepreneurs to brands like Aldo, BarkBox, Carrier, Meta, Vuori, SKIMS, and Supreme.

For more information, visit www.shopify.com.

CONTACT INVESTORS:		CONTACT MEDIA:
Shane Kleinstein		Jackie Warren
Director, Investor Relations		Senior Lead, Communications
IR@shopify.com		press@shopify.com

Internet, Everywhere, Oct. 06, 2026 (GLOBE NEWSWIRE) — Shopify Inc. (NASDAQ, TSX: SHOP) plans to announce financial results for the quarter ended September 30, 2026 before markets open on Tuesday, November 3, 2026.

Shopify’s management team will host a conference call to discuss third-quarter results at 8:30 a.m. ET on Tuesday, November 3, 2026. The conference call will be available via webcast on the Investor Relations section of Shopify’s website at https://www.shopify.com/investors/events.

An archived replay of the webcast will be available following the conclusion of the call.

About Shopify

Shopify provides essential internet infrastructure for commerce. Shopify’s all-in-one platform makes it easier to start, run, and grow a business, powering sales online, in store, and everywhere in between. Millions of businesses in 175+ countries use Shopify—from entrepreneurs to brands like Aldo, BarkBox, Carrier, Meta, Vuori, SKIMS, and Supreme.

For more information, visit www.shopify.com.

CONTACT INVESTORS:		CONTACT MEDIA:
Shane Kleinstein		Jackie Warren
Director, Investor Relations		Senior Lead, Communications
IR@shopify.com		press@shopify.com

Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030

REHOVOT, Israel and HOBOKEN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products.

The two newly launched biosimilar products are Ustekinumab-Kamada, a biosimilar to Stelara®, a monoclonal antibody indicated for the treatment of chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane®, a low-molecular-weight heparin indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for use in certain acute coronary syndrome settings.

The launch of the new products is in addition to the Company’s first two biosimilar products, Bevacizumab-Kamada, a biosimilar to Avastin® (Bevacizumab), and Pegfilgrastim-Kamada, a biosimilar to Neulasta®, which were launched in the Israeli market over the last two years. The Company expects the commercial availability of at least two additional biosimilar products during 2027.

All four biosimilar products were approved and launched as interchangeable with the reference original biologic product.

Kamada’s existing commercial portfolio of biosimilars is anticipated to generate approximately $4 million in sales in 2026, growing to approximately $10 million in 2028. By 2030, the Company expects this strategic portfolio to include at least 12 marketed products, licensed from 6 different leading international biosimilar companies, to be commercialized in Israel and the Middle East and North Africa (MENA) region, with the expectation to generate between approximately $20 million to $25 million in annual revenue. Kamada expects that additional biosimilar products, licensed by Kamada, will be in development or registration phase by 2030, contributing to further meaningful expansion of the portfolio.

“Kamada is building a growing and diversified biosimilars portfolio across key therapeutic areas. Our biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region make us an attractive in-licensing partner, and we are pleased to have launched two additional biosimilars,” said Amir London, Kamada’s Chief Executive Officer. “The growth of our biosimilar product portfolio is one of our key strategic growth pillars. We continue to evaluate additional licensing opportunities that offer attractive commercial potential, and we expect this portfolio to become a meaningful contributor to our overall annual revenue growth in the years ahead.”

About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) the expected expansion, composition and geographic reach of Kamada’s biosimilar product portfolio; 2) the anticipated timing of the commercial availability and launch of additional biosimilar products; 3) the expected sales and annual revenue contribution of Kamada’s biosimilar product portfolio, including the anticipated generation of approximately $4 million in sales in 2026, approximately $10 million in sales in 2028 and approximately $20 million–$25 million in annual revenue by 2030; 4) the expected number of marketed biosimilar products and licensing partners by 2030; 5) the development or registration status of additional licensed biosimilar products and their potential contribution to further portfolio expansion; 6) Kamada’s ability to leverage its biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region to remain an attractive in-licensing partner and to identify, evaluate, enter into and successfully commercialize additional in-licensing opportunities that offer attractive commercial potential; and 7) the anticipated contribution of Kamada’s biosimilar product portfolio to its future annual revenue growth, including the expectation that the portfolio will become a meaningful contributor to such growth in the years ahead. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, the effect of tariffs on overall international trade and specifically on Kamada’s ability to continue maintaining expected sales and profit levels in light of such tariffs, the effect on the establishment and timing of business initiatives, Kamada’s ability to find business development and M&A transactions and leverage such opportunities and successfully integrate such opportunities with its existing product portfolio, unexpected results of clinical and development programs, regulatory delays, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030

REHOVOT, Israel and HOBOKEN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products.

The two newly launched biosimilar products are Ustekinumab-Kamada, a biosimilar to Stelara®, a monoclonal antibody indicated for the treatment of chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane®, a low-molecular-weight heparin indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for use in certain acute coronary syndrome settings.

The launch of the new products is in addition to the Company’s first two biosimilar products, Bevacizumab-Kamada, a biosimilar to Avastin® (Bevacizumab), and Pegfilgrastim-Kamada, a biosimilar to Neulasta®, which were launched in the Israeli market over the last two years. The Company expects the commercial availability of at least two additional biosimilar products during 2027.

All four biosimilar products were approved and launched as interchangeable with the reference original biologic product.

Kamada’s existing commercial portfolio of biosimilars is anticipated to generate approximately $4 million in sales in 2026, growing to approximately $10 million in 2028. By 2030, the Company expects this strategic portfolio to include at least 12 marketed products, licensed from 6 different leading international biosimilar companies, to be commercialized in Israel and the Middle East and North Africa (MENA) region, with the expectation to generate between approximately $20 million to $25 million in annual revenue. Kamada expects that additional biosimilar products, licensed by Kamada, will be in development or registration phase by 2030, contributing to further meaningful expansion of the portfolio.

“Kamada is building a growing and diversified biosimilars portfolio across key therapeutic areas. Our biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region make us an attractive in-licensing partner, and we are pleased to have launched two additional biosimilars,” said Amir London, Kamada’s Chief Executive Officer. “The growth of our biosimilar product portfolio is one of our key strategic growth pillars. We continue to evaluate additional licensing opportunities that offer attractive commercial potential, and we expect this portfolio to become a meaningful contributor to our overall annual revenue growth in the years ahead.”

About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) the expected expansion, composition and geographic reach of Kamada’s biosimilar product portfolio; 2) the anticipated timing of the commercial availability and launch of additional biosimilar products; 3) the expected sales and annual revenue contribution of Kamada’s biosimilar product portfolio, including the anticipated generation of approximately $4 million in sales in 2026, approximately $10 million in sales in 2028 and approximately $20 million–$25 million in annual revenue by 2030; 4) the expected number of marketed biosimilar products and licensing partners by 2030; 5) the development or registration status of additional licensed biosimilar products and their potential contribution to further portfolio expansion; 6) Kamada’s ability to leverage its biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region to remain an attractive in-licensing partner and to identify, evaluate, enter into and successfully commercialize additional in-licensing opportunities that offer attractive commercial potential; and 7) the anticipated contribution of Kamada’s biosimilar product portfolio to its future annual revenue growth, including the expectation that the portfolio will become a meaningful contributor to such growth in the years ahead. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, the effect of tariffs on overall international trade and specifically on Kamada’s ability to continue maintaining expected sales and profit levels in light of such tariffs, the effect on the establishment and timing of business initiatives, Kamada’s ability to find business development and M&A transactions and leverage such opportunities and successfully integrate such opportunities with its existing product portfolio, unexpected results of clinical and development programs, regulatory delays, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) — The Simply Good Foods Company (NASDAQ: SMPL) (“Simply Good Foods” or the “Company”), a leader in the Nutritional Snacking category, today announced it will report financial results for the fourth quarter of Fiscal Year 2026 on Tuesday, October 27, 2026. A press release will be issued that morning, followed by a live conference call beginning at 6:30 a.m. Mountain Time (8:30 a.m. Eastern Time). Participating on the call will be Joe Scalzo, President and Chief Executive Officer and Chris Bealer, Chief Financial Officer.

Investors interested in participating in the live call can dial 877-407-0792 from the U.S., or 201-689-8263 from international locations. A live webcast, as well as a supplemental slide presentation, will be available via the “Investors” section of the Company’s website at www.thesimplygoodfoodscompany.com.

A telephone replay will be available approximately two hours after the call concludes and will remain accessible through Tuesday, November 10, 2026, by dialing 844-512-2921 from the U.S., or 412-317-6671 from international locations, and entering confirmation code 13762620.

About The Simply Good Foods Company
The Simply Good Foods Company (Nasdaq: SMPL), headquartered in Denver, Colorado, is a consumer-packaged food and beverage company with ambitious goals to raise the bar on what food can be with trusted brands and innovative nutritious snacking products. Within our portfolio of trusted brands (Quest™, Atkins™, and OWYN™), we offer a wide variety of nutritional snacks and beverages, including high protein chips, bars, ready-to-drink (RTD) shakes, and powders, and low sugar, low carb sweets and baked goods. We are a leader of the nutritious snacking movement, poised to expand our healthy lifestyle platform through innovation-driven organic growth and external investment opportunities. To learn more, visit www.thesimplygoodfoodscompany.com.

Investor Contact
Matt Siler
Vice President, Investor Relations and Treasury
The Simply Good Foods Company
msiler@simplygoodfoodsco.com

DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) — The Simply Good Foods Company (NASDAQ: SMPL) (“Simply Good Foods” or the “Company”), a leader in the Nutritional Snacking category, today announced it will report financial results for the fourth quarter of Fiscal Year 2026 on Tuesday, October 27, 2026. A press release will be issued that morning, followed by a live conference call beginning at 6:30 a.m. Mountain Time (8:30 a.m. Eastern Time). Participating on the call will be Joe Scalzo, President and Chief Executive Officer and Chris Bealer, Chief Financial Officer.

Investors interested in participating in the live call can dial 877-407-0792 from the U.S., or 201-689-8263 from international locations. A live webcast, as well as a supplemental slide presentation, will be available via the “Investors” section of the Company’s website at www.thesimplygoodfoodscompany.com.

A telephone replay will be available approximately two hours after the call concludes and will remain accessible through Tuesday, November 10, 2026, by dialing 844-512-2921 from the U.S., or 412-317-6671 from international locations, and entering confirmation code 13762620.

About The Simply Good Foods Company
The Simply Good Foods Company (Nasdaq: SMPL), headquartered in Denver, Colorado, is a consumer-packaged food and beverage company with ambitious goals to raise the bar on what food can be with trusted brands and innovative nutritious snacking products. Within our portfolio of trusted brands (Quest™, Atkins™, and OWYN™), we offer a wide variety of nutritional snacks and beverages, including high protein chips, bars, ready-to-drink (RTD) shakes, and powders, and low sugar, low carb sweets and baked goods. We are a leader of the nutritious snacking movement, poised to expand our healthy lifestyle platform through innovation-driven organic growth and external investment opportunities. To learn more, visit www.thesimplygoodfoodscompany.com.

Investor Contact
Matt Siler
Vice President, Investor Relations and Treasury
The Simply Good Foods Company
msiler@simplygoodfoodsco.com

Shareholder Support for the Merger Remains Strong with New Record Date and Shareholder Meeting to be Rescheduled

LT350 Opportunity Accelerates into National AI Infrastructure Narrative

Expanded AI Infrastructure Opportunity Since Original Record Date

BOULDER, Colo., Oct. 06, 2026 (GLOBE NEWSWIRE) — Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI-first technology company pursuing a merger that, if completed, would form McCarthy Finney, an AI-native operating company, today announced the cancellation of the special shareholder meeting that was originally scheduled for September 23, 2026, but was previously adjourned to October 7, 2026. The purpose of the meeting was to vote on the Company’s proposed merger with Thramann Holdings.

Approximately 89% of votes cast on the merger were in favor of transaction, reflecting strong shareholder alignment with the Company’s strategic direction. Under Delaware law, the merger requires approval by a majority of the outstanding common shares entitled to vote at the meeting. The number of favorable votes cast was less than this required level. Our proxy solicitation advisors indicated that insufficient additional shareholders could be located from the established record date of August 3, 2026 and that this was unlikely to change.

Since the original record date, Auddia has experienced a significant expansion in strategic momentum, driven primarily by the emergence of LT350, a subsidiary of Thramann Holdings that would become a subsidiary of MCFN upon closing of the proposed merger. LT350 is developing a patented distributed datacenter platform designed to meet rapidly growing AI inference demand. LT350’s architecture deploys datacenter grade GPU infrastructure in the airspace of existing parking lots, a structural advantage that directly addresses the community resistance bottlenecks slowing datacenter expansion nationwide.

This momentum has carried over to LT350 gaining national and local attention as a common sense solution to the community resistance issues facing other data centers as evidenced by recent appearances on Fox Business News’ Varney & Co., Bloomberg News Network, Fox 17 Nashville, as well as multiple interviews with print outlets. This has accelerated the initiation of discussions with several strategic partners across fiber, real estate, enterprise, and hyperscaler ecosystems. These developments have materially increased both the clarity and magnitude of the LT350 opportunity underlying the merger.

“We are encouraged by the strong shareholder support reflected in the votes that were cast for the merger,” said Jeff Thramann, CEO of Auddia and Founder of LT350. “At the same time, the momentum surrounding LT350 has accelerated dramatically. The distributed datacenter opportunity is larger and more strategically important than previously understood, and we want shareholders to have full visibility into this growth before voting. Canceling the meeting now, as opposed to a further adjournment, allows us to align the merger vote with this expanded opportunity.”

The Company will issue a CEO Letter to Shareholders later this week providing a comprehensive update on Auddia’s progress throughout 2026, including recent developments related to LT350 and the company’s broader AI-infrastructure strategy. Following this update, and the additional announcements expected to follow, Auddia expects to establish a new record date and reschedule the shareholder meeting to vote on the proposed merger.

The Company will continue to provide updates as the process advances.

About the Merger to form McCarthy Finney (MCFN)

Auddia entered into a definitive merger agreement with Thramann Holdings, LLC on February 17, 2026. If completed, the transaction would combine Auddia with three early-stage, AI-native operating companies wholly owned by Thramann Holdings: LT350, Influence Healthcare, and Voyex. The combined company would be renamed McCarthy Finney Inc. and is expected to trade under the ticker MCFN, subject to applicable approvals and listing requirements. McCarthy Finney would operate as an AI holding company supporting LT350, Influence Healthcare, Voyex, and Auddia with AI and Web3 capabilities.

• LT350 is a distributed AI datacenter company with 14 issued patents and 3 pending patent applications covering its proprietary solar parking lot canopy infrastructure platform. The platform integrates modular battery storage and GPU cartridges into the canopy ceiling to convert the airspace of underutilized parking areas into distributed AI datacenters. LT350 aims to build a secure, low latency, cost effective, and rapidly deployable edge network while supporting local power infrastructure resilience.
• Influence Healthcare is a healthtech company leveraging AI, blockchain, and vertical integration to empower surgeons to drive adoption of value based care (VBC) to the surgical specialties. The Company’s mission is to leverage technology and value based enterprises (VBEs) to build an alternative healthcare system that minimizes the corporate practice of medicine, eliminates administrative waste, and enhances the autonomy and pay of health care providers to empower them to improve quality and return the patient physician relationship to the center of medicine.
• Voyex is a travel services platform that leverages agentic AI, an integrated fintech platform, and utilization of charter and private jet aircraft to significantly improve the travel experience. The Company aims to alleviate the leading pain points for travelers of lengthy flight delays and cancellations.

About Auddia Inc.

Auddia, through its proprietary AI platform for audio identification and classification, is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. Auddia’s Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Auddia’s flagship audio superapp, called faidr, delivers multiple industry firsts, including:

• Ad-free listening on any AM/FM radio station
• Content skipping across any AM/FM station
• One-touch skipping of entire podcast ad breaks
• Integrated artist discovery experiences

For more information, visit www.auddia.com.

Cautionary Note on Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995, concerning Auddia, Thramann Holdings, and the proposed merger between Auddia and Thramann Holdings (the “Proposed Transaction”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Auddia’s and Thramann Holdings’ management expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the structure, timing and completion of the proposed merger by and between Auddia and Thramann Holdings, and the expected effects, perceived benefits or opportunities of the Proposed Transaction; the combined company’s listing on Nasdaq after the closing of the Proposed Transaction; expectations regarding the structure, timing and completion of the financing needed to close the Proposed Transaction, including investment amounts from investors, timing of closing of the Proposed Transaction, expected proceed, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the closing; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing and cash runway of the combined company following the proposed merger and any additional financing; the future operations of the combined company, including research and development activities; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any products and services of the combined company; the cash balance of the combined entity at closing; expectations related to the anticipated timing of the closing of the Proposed Transaction (the “Closing”); the expectations regarding the ownership structure of the combined company; the expected trading of the combined company’s stock on Nasdaq under the ticker symbol “MCFN” after the Closing; and other statements that are not historical fact.

All statements other than statements of historical fact contained in this communication are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are made based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, concerning future developments and their potential effects. There can be no assurance that future developments affecting Auddia, Thramann Holdings, or the Proposed Transaction will be those that have been anticipated.

These forward-looking statements involve a number of risks and uncertainties, some of which are beyond Auddia’s or Thramann Holdings’ control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the Closing or consummation of the Proposed Transaction are not satisfied, including the failure to timely obtain approval of the proposed merger from Auddia’s stockholders the risk that the required financing is not obtained in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transaction; risks related to Auddia’s continued listing on Nasdaq until closing of the Proposed Transaction and the combined company’s ability to remain listed following the Closing; uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the merger on Auddia’s or Thramann Holdings’ business relationships, operating results and business generally; costs related to the merger; the risk that as a result of adjustments to the exchange ratio, Auddia’s or Thramann Holdings’ stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Auddia’s common stock relative to the value suggested by the exchange ratio; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the development of its products and services; costs of the Proposed Transaction and unexpected costs, charges or expenses resulting from the Proposed Transaction; potential adverse reactions or changes to business relationships, operating results, and business generally, resulting from the announcement or completion of the Proposed Transaction.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Auddia’s Annual Report on Form 10-K for the year ended December 31, 2025, which was originally filed with the SEC on March 6, 2026, subsequent Quarterly Reports on Form 10-Q filed with the SEC, and in other filings that Auddia makes and will make with the SEC in connection with the Proposed Transaction, including the Form S-4 and Proxy Statement described below, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Auddia from time to time. Should one or more of these risks or uncertainties materialize, or should any of Auddia’s or Thramann Holdings’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither Auddia nor Thramann Holdings undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Auddia or Thramann Holdings.

No Offer or Solicitation

This communication and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

Important Additional Information about the Proposed Transaction Will be Filed with the SEC

This communication relates to the proposed merger involving Auddia and Thramann Holdings and may be deemed to be solicitation material in respect of the proposed merger. In connection with the proposed Transaction, Auddia intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document that Auddia may file with the SEC and/or send to Auddia’s stockholders in connection with the proposed merger. AUDDIA URGES, BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AUDDIA, THRAMANN HOLDINGS, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Auddia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed by Auddia with the SEC will also be available free of charge on Auddia’s website at www.auddia.com or by contacting Auddia Investor Relations at investors.auddiainc.com/contact. In addition, investors and stockholders should note that Auddia communicates with investors and the public through its investor-relations website at investors.auddiainc.com.

Participants in the Solicitation

Auddia, Thramann Holdings, and their respective directors and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from Auddia’s stockholders in connection with the proposed transaction under the rules of the SEC. Information about Auddia’s directors and executive officers, including a description of their interests in Auddia, is included in Auddia’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 6, 2026. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including about the directors and executive officers of Thramann Holdings, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

Investor Relations:
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
www.pcgadvisory.com